Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases

Morishige Takeshita, Shuhei Imayama, Yumi Oshiro, Kenji Kurihara, Sumika Okamoto, Yasumasa Matsuki, Yutaka Nakashima, Takashi Okamura, Motoaki Shiratsuchi, Toru Hayashi, Masahiro Kikuchi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)βF1 + (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRβF1 + (3/10 [30%]), and CD95 (Fas) + (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.

Original languageEnglish
Pages (from-to)408-416
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume121
Issue number3
DOIs
Publication statusPublished - Jan 1 2004

Fingerprint

Panniculitis
Lymphoma
Skin Ulcer
Dermis
Neoplasms
Natural Killer Cells
T-Lymphocytes
T-Cell Lymphoma
T-Cell Antigen Receptor
Human Herpesvirus 4
RNA
Phenotype

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases. / Takeshita, Morishige; Imayama, Shuhei; Oshiro, Yumi; Kurihara, Kenji; Okamoto, Sumika; Matsuki, Yasumasa; Nakashima, Yutaka; Okamura, Takashi; Shiratsuchi, Motoaki; Hayashi, Toru; Kikuchi, Masahiro.

In: American Journal of Clinical Pathology, Vol. 121, No. 3, 01.01.2004, p. 408-416.

Research output: Contribution to journalArticle

Takeshita, M, Imayama, S, Oshiro, Y, Kurihara, K, Okamoto, S, Matsuki, Y, Nakashima, Y, Okamura, T, Shiratsuchi, M, Hayashi, T & Kikuchi, M 2004, 'Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases', American Journal of Clinical Pathology, vol. 121, no. 3, pp. 408-416. https://doi.org/10.1309/TYRGT196N2APLLR9
Takeshita, Morishige ; Imayama, Shuhei ; Oshiro, Yumi ; Kurihara, Kenji ; Okamoto, Sumika ; Matsuki, Yasumasa ; Nakashima, Yutaka ; Okamura, Takashi ; Shiratsuchi, Motoaki ; Hayashi, Toru ; Kikuchi, Masahiro. / Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases. In: American Journal of Clinical Pathology. 2004 ; Vol. 121, No. 3. pp. 408-416.
@article{24bcaff4f3994789a179b06d0aa3d910,
title = "Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases",
abstract = "In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9{\%}]); tumor invasion in the superficial dermis (1 [9{\%}]); erythrophagocytosis (10 [91{\%}]); and medium-sized (11 [100{\%}]), CD8+ (10 [91{\%}]), T-cell receptor (TcR)βF1 + (10 [91{\%}]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82{\%}]); tumor invasion in the superficial dermis (8 [73{\%}]); erythrophagocytosis (1 [9{\%}]); and pleomorphic large (10 [91{\%}]), CD8+ (2/10 [20{\%}]), TcRβF1 + (3/10 [30{\%}]), and CD95 (Fas) + (7/10 [70{\%}]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.",
author = "Morishige Takeshita and Shuhei Imayama and Yumi Oshiro and Kenji Kurihara and Sumika Okamoto and Yasumasa Matsuki and Yutaka Nakashima and Takashi Okamura and Motoaki Shiratsuchi and Toru Hayashi and Masahiro Kikuchi",
year = "2004",
month = "1",
day = "1",
doi = "10.1309/TYRGT196N2APLLR9",
language = "English",
volume = "121",
pages = "408--416",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases

AU - Takeshita, Morishige

AU - Imayama, Shuhei

AU - Oshiro, Yumi

AU - Kurihara, Kenji

AU - Okamoto, Sumika

AU - Matsuki, Yasumasa

AU - Nakashima, Yutaka

AU - Okamura, Takashi

AU - Shiratsuchi, Motoaki

AU - Hayashi, Toru

AU - Kikuchi, Masahiro

PY - 2004/1/1

Y1 - 2004/1/1

N2 - In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)βF1 + (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRβF1 + (3/10 [30%]), and CD95 (Fas) + (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.

AB - In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)βF1 + (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRβF1 + (3/10 [30%]), and CD95 (Fas) + (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.

UR - http://www.scopus.com/inward/record.url?scp=10744231158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744231158&partnerID=8YFLogxK

U2 - 10.1309/TYRGT196N2APLLR9

DO - 10.1309/TYRGT196N2APLLR9

M3 - Article

VL - 121

SP - 408

EP - 416

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -